AbCellera Biologics (ABCL) Current Assets (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Current Assets came in at $664.6 million in Q1 2026, down 13.12% YoY from $765.0 million in Q1 2025, and down 8.74% on a QoQ basis from $728.2 million in Q4 2025.
AbCellera Biologics (ABCL) Current Assets (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Current Assets data on file, last reported at $664.6 million in Q1 2026.
- Quarterly Current Assets fell 13.12% year-over-year to $664.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $664.6 million (down 13.12% YoY) and the FY2025 annual result came in at $728.2 million, down 3.08% from the prior year.
- Current Assets eased to $664.6 million in Q1 2026, from $728.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.2 billion in Q1 2022 to a low of $664.6 million in Q1 2026.
- A 5-year average of $866.3 million and a median of $813.9 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets soared 32.4% — and 2023, when it declined 19.9%.
- Tracing ABCL's Current Assets over 5 years: stood at $1.0 billion in 2022, then dropped by 14.97% to $872.0 million in 2023, then slipped by 13.83% to $751.4 million in 2024, then dropped by 3.08% to $728.2 million in 2025, then declined by 8.74% to $664.6 million in 2026.
- The last three Current Assets figures came in at $664.6 million (Q1 2026), $728.2 million (Q4 2025), and $695.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 679.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 679.23 Mn |
| Mar 31, 2026 | 664.60 Mn |
| Dec 31, 2025 | 728.23 Mn |
| Sep 30, 2025 | 695.14 Mn |
| Jun 30, 2025 | 742.15 Mn |
| Mar 31, 2025 | 764.98 Mn |
| Dec 31, 2024 | 751.37 Mn |
| Sep 30, 2024 | 742.88 Mn |
| Jun 30, 2024 | 771.55 Mn |
| Mar 31, 2024 | 813.95 Mn |
| Dec 31, 2023 | 871.99 Mn |
| Sep 30, 2023 | 919.52 Mn |
| Jun 30, 2023 | 930.74 Mn |
| Mar 31, 2023 | 940.65 Mn |
| Dec 31, 2022 | 1.03 Bn |
| Sep 30, 2022 | 1.05 Bn |
| Jun 30, 2022 | 1.14 Bn |
| Mar 31, 2022 | 1.17 Bn |
| Dec 31, 2021 | 929.80 Mn |
| Sep 30, 2021 | 803.75 Mn |